Investor Relations

Investors

Investor Relations

Corporate Profile

Anpac Bio is a biotechnology company focusing on early cancer screening and detection and marketing a suite of cancer detection tests, including CDA (cancer differentiation analysis), bio-chemistry, immunology, and genomics tests. Anpac has developed a multi-cancer screening and detection test that uses innovative, patented CDA technology and proprietary cancer-detection device.

Press Releases

Aug 07, 2020

AnPac Bio Validating Approved COVID-19 Antibody Test

SAN JOSE, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States announced today that the Company has been validating the approved COVID-19 antibody

Aug 04, 2020

AnPac Bio Announces Preliminary Results From Prospective Trials Indicating Early-Stage Cancer Screening Effectiveness

SAN JOSE, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today preliminary results

Jul 29, 2020

AnPac Bio Completes Over 180,000 CDA-Based Cancer Risk Assessment Tests

SAN JOSE, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today it had completed over

Stock Quote

Change

Volume

52 Week High

52 Week Low

Aug 9, 2020 4:35 AM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Events

More events are coming soon.

Investors

Investor Relations

Corporate Profile

Stock Quote

Quick Links

Contact Information